Core Viewpoint - ProQR Therapeutics is entering a significant growth phase with its Axiomer RNA editing platform, anticipating multiple clinical trial data readouts in 2025 and 2026, which could demonstrate the therapeutic potential of RNA editing [2][5]. Financial Highlights - As of December 31, 2024, ProQR held cash and cash equivalents of €149.4 million, an increase from €118.9 million at the end of 2023 [7]. - The net cash used in operating activities for the year ended December 31, 2024, was €36.4 million, compared to a net cash generation of €21.5 million in 2023 [7]. - Research and development costs for 2024 were €36.4 million, up from €25.1 million in 2023, reflecting increased investments in the platform and pipeline programs [8]. - The net loss for 2024 was €27.8 million, or €0.32 per diluted share, compared to a net loss of €27.7 million, or €0.35 per diluted share in 2023 [9]. Recent Progress - ProQR expanded its collaboration with the Rett Syndrome Research Trust, securing up to $9.2 million for advancing AX-2402 into clinical trials [6]. - The company appointed Dr. Peter A. Beal as Chief ADAR Scientist to enhance the development of its Axiomer platform [6]. - In October 2024, ProQR completed a public offering and private placement, raising approximately $82.1 million [6]. Anticipated Upcoming Events - The company plans to submit a Clinical Trial Application (CTA) for AX-0810 in Q2 2025, with the first clinical data readout expected in Q4 2025 [5][6]. - ProQR anticipates up to four clinical data readouts in 2025 and 2026 across various programs, including AX-2402 for Rett Syndrome and AX-2911 for MASH [5][13].

Revenue and Income - Total revenue for the three months ended September 30, 2024, was €3,843 million, a significant increase from €1,370 million in the same period of 2023, representing a growth of 180%[10] - The company’s total revenue from grant income for the nine-month period ended September 30, 2024, was €504,000, significantly higher than €76,000 for the same period in 2023, marking an increase of over 563%[89] Expenses and Costs - Research and development costs for the nine months ended September 30, 2024, were €25,745 million, compared to €17,415 million for the same period in 2023, reflecting an increase of 48%[10] - General and administrative costs decreased to €9,748,000 for the nine-month period ended September 30, 2024, down from €11,486,000 in the same period of 2023[17] - The company’s share-based compensation expenses for the nine-month period ended September 30, 2024, were €1,976,000, down from €2,304,000 for the same period in 2023, reflecting a decrease of approximately 14%[73] Financial Position - Total assets decreased to €106,851 million as of September 30, 2024, down from €137,883 million at the end of 2023, a decline of 22.5%[6] - Total equity attributable to owners of the Company was €24,982 million as of September 30, 2024, down from €41,390 million at the end of 2023, a decrease of 39.5%[6] - Total liabilities decreased to €81,869 million as of September 30, 2024, down from €96,493 million at the end of 2023, a decline of 15.1%[6] - Cash and cash equivalents decreased to €89,401 million as of September 30, 2024, from €118,925 million at the end of 2023, a reduction of 25%[6] Losses and Earnings - The operating result for the three months ended September 30, 2024, was a loss of €8,716 million, compared to a loss of €7,391 million in the same period of 2023[10] - The company reported a total comprehensive loss of €18,559 million for the nine months ended September 30, 2024, compared to a loss of €22,799 million in the same period of 2023, indicating a reduction in losses of 18.8%[10] - Basic loss per share for the nine months ended September 30, 2024, was €0.23, an improvement from €0.28 in the same period of 2023[10] - For the three months ended September 30, 2024, the net result was a loss of €8,108,000 compared to a loss of €5,420,000 for the same period in 2023[17] Cash Flow and Activities - Cash used in operating activities for the nine months ended September 30, 2024, was €29,046,000, a significant decrease from cash generated of €25,120,000 in the same period of 2023[17] - The company reported a net cash generated by investing activities of €16,714,000 for the three months ended September 30, 2024, compared to a cash used of €339,000 in the same period of 2023[17] - The company recognized interest received of €860,000 for the three months ended September 30, 2024, compared to €802,000 in the same period of 2023[17] Deferred Revenue and Payments - The total deferred revenue balance as of September 30, 2024, was €55,588,000, with €55,236,000 related to the Eli Lilly performance obligation[39] - During the nine-month period ended September 30, 2024, the company recognized milestone payments of $5,500,000 (€5,094,000) under its collaboration agreement with Eli Lilly[88] - The company received an upfront payment of $60,000,000 (€56,412,000) in February 2023 under the amended collaboration agreement with Eli Lilly, which was recognized under deferred income[82] Investments and Financial Assets - The company has invested in financial assets with an original maturity of longer than three months but shorter than twelve months during the nine-month period ended September 30, 2024[27] - ProQR holds a 3.9% interest in Phoenicis Therapeutics Inc., which discontinued operations in Q3 2024, resulting in a fair value loss recognized in other comprehensive income[96] - ProQR holds a 5.1% interest in Yarrow Biotechnology Inc., with the fair value of this financial asset remaining at €nil as of September 30, 2024[97] Other Financial Metrics - The carrying amount of the right-of-use asset related to the lease of the Leiden office and laboratory space was €11,873,000 as of September 30, 2024, down from €14,524,000 as of December 31, 2023, a decrease of about 18%[55] - Other current liabilities decreased to €7,439,000 as of September 30, 2024, from €8,509,000 as of December 31, 2023, indicating a reduction of approximately 13%[56] - The income tax benefit for the nine-month period ended September 30, 2024, amounted to €197,000, an increase from €83,000 in the same period of 2023, consisting of refunds received for prior years[103] Company Outlook - The company expects to continue as a going concern based on its existing funding and projected cash flows[29] - No significant temporary differences exist between accounting and tax results, and the current income tax liability is €nil as of September 30, 2024[102] - The amount of convertible loans waived under agreements with Amylon in the nine-month period ended September 30, 2024, is €nil, compared to €1,866,000 in the same period of 2023[100] - Amylon Therapeutics B.V. was legally dissolved in Q3 2023, impacting the company's financial liabilities[101]

Core Viewpoint - ProQR Therapeutics has announced a public offering of 18 million ordinary shares at a price of $3.50 per share, aiming to raise approximately $63 million in gross proceeds to fund research and development initiatives [1][3]. Group 1: Offering Details - The public offering consists of 18,000,000 ordinary shares priced at $3.50 each, totaling gross proceeds of $63 million before expenses [1]. - ProQR has granted underwriters a 30-day option to purchase up to 2,700,000 additional shares at the public offering price [1]. - The offering is expected to close on October 24, 2024, subject to customary closing conditions [4]. Group 2: Concurrent Private Placement - ProQR has entered into a share purchase agreement with Eli Lilly to sell 3,523,538 ordinary shares, allowing Lilly to maintain its 16.4% ownership stake post-offering [2]. - The shares sold to Lilly will generate approximately $12.3 million in gross proceeds, with a purchase price cap of $15 million [2]. - The private placement shares will not be registered as part of the public offering and are exempt from registration under the Securities Act [3][6]. Group 3: Use of Proceeds - ProQR intends to use the net proceeds from both the public offering and the private placement primarily for research and development, clinical development, and expansion of its programs [3]. - Remaining funds will be allocated for working capital, capital expenditures, and other general corporate purposes [3]. Group 4: Company Overview - ProQR Therapeutics focuses on developing transformative RNA therapies using its proprietary Axiomer™ RNA editing technology [7]. - The company aims to create a new class of medicines targeting both rare and prevalent diseases with unmet medical needs [7].

Core Viewpoint - ProQR Therapeutics has initiated an underwritten public offering of its ordinary shares to fund research and development, clinical development, and general corporate purposes [1][2]. Group 1: Offering Details - The offering includes a 30-day option for underwriters to purchase an additional 15% of the offering amount at the public offering price [1]. - The offering is subject to market conditions, and there is no assurance regarding its completion or terms [1]. Group 2: Use of Proceeds - ProQR plans to utilize the net proceeds from the offering, along with existing cash, primarily for research and development and clinical development of current and future product candidates [2]. - Remaining funds will be allocated for working capital, capital expenditures, and other general corporate purposes [2]. Group 3: Regulatory Filings - A shelf registration statement on Form F-3 was filed with the SEC on September 30, 2024, and became effective on October 10, 2024 [3]. - A preliminary prospectus supplement will be filed with the SEC to describe the terms of the offering [3]. Group 4: Company Overview - ProQR Therapeutics focuses on transformative RNA therapies using its proprietary Axiomer™ RNA editing technology platform [5]. - The Axiomer™ technology aims to make specific single nucleotide edits in RNA, potentially leading to new medicines for both rare and prevalent diseases [5].

Core Insights - ProQR Therapeutics announced the presentation of preclinical data for its Axiomer™ RNA editing technology and AX-0810 pipeline program targeting cholestatic diseases at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society [1][2] Group 1: Axiomer™ Technology - Axiomer™ is a next-generation RNA base editing technology that allows for specific single nucleotide changes in RNA, potentially leading to new medicines for various diseases [3][4] - The technology utilizes the human cell's own ADAR machinery to convert Adenosine (A) to Inosine (I), which is then translated as Guanosine (G), effectively correcting disease-causing mutations [3] Group 2: Pipeline and Therapeutic Focus - The AX-0810 program specifically targets NTCP to lower bile acid reuptake in cholestatic diseases, with a presentation scheduled for October 8, 2024 [2] - ProQR aims to address both rare and prevalent diseases with unmet medical needs through its proprietary RNA repair platform [4]

Financial Performance - Total revenue for Q2 2024 reached €6,305 thousand, a significant increase from €1,205 thousand in Q2 2023, representing a growth of 424%[6] - The operating result for Q2 2024 was a loss of €3,600 thousand, an improvement compared to a loss of €8,811 thousand in Q2 2023, reflecting a reduction in losses by 59%[6] - The total comprehensive income for the six months ended June 30, 2024, was a loss of €10,074 thousand, compared to a loss of €17,044 thousand in the same period of 2023, showing an improvement of 41%[6] - Basic loss per share for Q2 2024 was €(0.03), an improvement from €(0.10) in Q2 2023[6] - For the three months ended June 30, 2024, the net result was a loss of €2,692,000, an improvement from a loss of €7,977,000 in the same period last year, representing a 66.2% reduction in losses[8] Research and Development - Research and development costs for the six months ended June 30, 2024, were €16,331 thousand, up from €11,969 thousand in the same period of 2023, indicating a rise of 36%[6] - Research and development expenditures are reflected in the income statement, with development expenses currently not capitalized due to unmet criteria[22] - Research and development costs for the six-month period ended June 30, 2024, increased to €16,331,000, compared to €11,969,000 for the same period in 2023, reflecting increased outsourced activities and full-time employee equivalents[49] Assets and Liabilities - Total assets decreased to €118,051 thousand as of June 30, 2024, down from €137,883 thousand at the end of 2023, a decline of 14%[3] - Equity attributable to owners of the Company fell to €32,854 thousand at June 30, 2024, down from €41,390 thousand at December 31, 2023, a decrease of 21%[3] - Cash and cash equivalents decreased to €578,970 thousand as of June 30, 2024, from €118,925 thousand at December 31, 2023, indicating a significant reduction in liquidity[3] - Total current liabilities increased to €37,279 thousand as of June 30, 2024, compared to €34,203 thousand at the end of 2023, an increase of 6%[3] - Other current liabilities decreased to €5,675,000 as of June 30, 2024, from €8,509,000 as of December 31, 2023[28] Cash Flow - Cash used in operating activities for the six months ended June 30, 2024, was €22,747,000, compared to cash generated of €33,513,000 in the same period last year, indicating a significant cash outflow[8] - The cash and cash equivalents at the end of the period were €78,970,000, down from €118,925,000 at December 31, 2023, reflecting a decrease of 33.5%[23] - Interest received during the three months ended June 30, 2024, was €610,000, compared to €685,000 in the same period last year, showing a decrease of 10.9%[8] - The company reported a net cash used in investing activities of €267,000 for the three months ended June 30, 2024, compared to €294,000 in the same period last year[8] Income and Grants - The company recognized grant income of €366,000 for the six-month period ended June 30, 2024, compared to €76,000 in the same period of 2023[47] - During the six-month period ended June 30, 2024, the company reached milestones amounting to $4,500,000 (€4,196,000) under its collaboration agreement with Eli Lilly[46] Borrowings and Tax - The company’s total borrowings as of June 30, 2024, amount to €4,437,000, an increase from €4,292,000 as of December 31, 2023[29] - The current income tax liability amounts to € nil as of June 30, 2024, consistent with December 31, 2023[54] - The company has not recognized any deferred tax asset related to operating losses due to uncertainty in future earnings[54] - Tax losses can be carried forward indefinitely, but offset against taxable profit is limited to the first € 1 million, with only 50% of excess profit eligible for offset[54] Company Structure and Operations - The company operates in one reportable segment focused on the discovery and development of innovative RNA-based therapeutics[15] - Amylon Therapeutics B.V., an 80% subsidiary, had convertible loans with an average interest rate of 8% per annum[53] - In the six-month period ended June 30, 2024, the amount of convertible loans and accumulated interest waived was € nil, compared to € 509,000 for the same period in 2023[53] - Amylon was legally dissolved in the third quarter of 2023[53]

The presentation will be available on ProQR's website under Presentations & Publications. Learn more about ProQR at www.proqr.com. Investor contact: Sarah Kiely ProQR Therapeutics N.V. T: +1 617 599 6228 skiely@proqr.com or Peter Kelleher LifeSci Advisors T: +1 617 430 7579 pkelleher@lifesciadvisors.com LEIDEN, Netherlands & CAMBRIDGE, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announ ...

Table of Contents Exhibit 99.1 PROQR THERAPEUTICS N.V. Index to Unaudited Condensed Consolidated Financial Statements | Unaudited Condensed Consolidated Statement of Financial Position at March 31, 2024 and December 31, 2023 | PAGE 1 | | --- | --- | | Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income for the | | | Three Month Periods ended March 31, 2024 and 2023 | 2 | | Unaudited Condensed Consolidated Statement of Changes in Equity for the Three Month Periods Ende ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ...

Exhibit 99.1 ProQR Announces Year End 2023 Operating and Financial Results LEIDEN, Netherlands & CAMBRIDGE, Mass., March 13, 2024 – ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer RNA editing technology platform, today reported its financial and operating results for the year ended December 31, 2023, and provided a business update. "Over the past year as we exclusively focused our strategy on RNA editi ...